1 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2008
|
2 |
ClinicalTrials.gov (NCT02388724) Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Patients With Erosive Esophagitis. U.S. National Institutes of Health.
|
3 |
ClinicalTrials.gov (NCT04753437) A Study of Vonoprazan in Adults With Helicobacter Pylori
|
4 |
ClinicalTrials.gov (NCT05189444) The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori
|
5 |
ClinicalTrials.gov (NCT03219723) Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"
|
6 |
ClinicalTrials.gov (NCT04167670) Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection
|
7 |
ClinicalTrials.gov (NCT06162949) Vonoprazan for Helicobacter Pylori Eradication in Adolescents
|
8 |
ClinicalTrials.gov (NCT05014334) Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication
|
9 |
ClinicalTrials.gov (NCT05874544) Rescue Therapy for Helicobacter Pylori Infection
|
10 |
ClinicalTrials.gov (NCT05419674) Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection
|
11 |
ClinicalTrials.gov (NCT05726734) Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial
|
|
|
|
|
|
|